11:37 AM EDT, 03/18/2025 (MT Newswires) -- Ocular Therapeutix's ( OCUL ) Axpaxli is "well poised" to fill a void in the market for treatments for eye disease wet AMD, or age-related macular degeneration, RBC Capital Markets said in a Tuesday note.

Ocular's long-acting treatment -- with its potential for only one to two injections a year -- may "take a chunk" of the $15 billion market for anti-VEGF, which is used to treat eye diseases like wet AMD, the report said. Axpaxli is currently in phase 3 trials for wet AMD.

RBC said checks with key opinion leaders suggested that 20% of patients would be early adopters of Ocular's wet AMD treatment. It is modeling about 10% market penetration and $1.4 billion in revenue by 2035 for Ocular's treatment.

RBC started Ocular coverage with a $17 price target and an outperform, speculative risk rating.

Price: 7.88, Change: -0.06, Percent Change: -0.76